Featured Research

from universities, journals, and other organizations

Preeclampsia: New blood test to assess risk of imminent delivery can reduce complications for mother and child, study suggests

Date:
October 21, 2011
Source:
Charité - Universitätsmedizin Berlin
Summary:
A blood test can help to assess whether a pregnant woman who suffers from pregnancy-induced hypertension, so-called preeclampsia, is at risk for an imminent delivery. This knowledge can be used to determine the due date as well as avoid complications for mother and child.

A blood test can help to assess whether a pregnant woman who suffers from pregnancy-induced hypertension, so-called preeclampsia, is at risk for an imminent delivery. This knowledge can be used to determine the due date as well as avoid complications for mother and child.

This was now reported by a team of scientists at Charité -- Universitätsmedizin Berlin in the American Journal of Obstetrics & Gynecology. The assay was put to the test in collaboration with Universitätsklinik Leipzig and five other European research centers.

Preeclampsia is the most common of the dangerous pregnancy complications. It is characterized by elevated blood pressure, protein in the urine and accumulation of excess fluid beneath the skin. If not treated in time, preeclampsia may progress to eclampsia, characterized by tonic-clonic seizures which can possibly result in maternal and infant death.

Dr. Stefan Verlohren from the Klinik für Geburtsmedizin and his team examined a total of 630 pregnant women. 388 of those were having a normal pregnancy whereas 164 suffered from preeclampsia. The scientists closely observed the remaining time of pregnancy in patients with preeclampsia. In cases where the concentration of two certain placenta-derived growth factors, so-called sFlt-1 and PlGF, exceeded a certain value the duration of pregnancy was significantly shorter. In patients with especially high test results delivery resulted within 48 hours.

"With this test we can assess the severity of preeclampsia and give a short-term prognosis of the disease course," explains Dr: Verlohren. Further studies will have to evaluate the test´s validity in women who have an elevated risk of developing preeclampsia.


Story Source:

The above story is based on materials provided by Charité - Universitätsmedizin Berlin. Note: Materials may be edited for content and length.


Journal Reference:

  1. Stefan Verlohren, Ignacio Herraiz, Olav Lapaire, Dietmar Schlembach, Manfred Moertl, Harald Zeisler, Pavel Calda, Wolfgang Holzgreve, Alberto Galindo, Theresa Engels, Barbara Denk, Holger Stepan. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American Journal of Obstetrics and Gynecology, 2011; DOI: 10.1016/j.ajog.2011.07.037

Cite This Page:

Charité - Universitätsmedizin Berlin. "Preeclampsia: New blood test to assess risk of imminent delivery can reduce complications for mother and child, study suggests." ScienceDaily. ScienceDaily, 21 October 2011. <www.sciencedaily.com/releases/2011/10/111020094339.htm>.
Charité - Universitätsmedizin Berlin. (2011, October 21). Preeclampsia: New blood test to assess risk of imminent delivery can reduce complications for mother and child, study suggests. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/10/111020094339.htm
Charité - Universitätsmedizin Berlin. "Preeclampsia: New blood test to assess risk of imminent delivery can reduce complications for mother and child, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/10/111020094339.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins